-
On May 20, 2026, Guardant Health received FDA approval for Guardant360 Liquid CDx, the largest FDA-approved liquid biopsy panel, integrating genomic and epigenomic data to guide treatment selection for advanced cancer patients.
-
The approval transfers seven existing companion diagnostic indications to the new assay and positions Guardant360 Liquid CDx as the only FDA-approved liquid biopsy that combines genomic and epigenomic profiling from a single blood draw.
-
We’ll explore how FDA approval of Guardant360 Liquid CDx, with its broader genomic footprint and higher sensitivity, reshapes Guardant Health’s investment narrative.
Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
Guardant Health Investment Narrative Recap
To own Guardant Health, you need to believe blood based cancer testing can grow into a large, durable business and that the company can eventually fund that growth without excessive dilution. The new FDA approval for Guardant360 Liquid CDx reinforces the near term catalyst of broader clinical adoption of its oncology platform, but it does not remove the central risk that high R&D and commercial spend, combined with ongoing losses and cash burn, could pressure shareholders if external funding is needed.
Among recent developments, the nationwide rollout of Shield colorectal cancer screening through Quest Diagnostics is particularly relevant. Together with Guardant360 Liquid CDx, it shows Guardant trying to build both a high end oncology franchise and a mass market screening business on the same multiomic Smart Platform. For investors, these twin growth legs could amplify upside if adoption and reimbursement hold, but they also raise the stakes around execution, pricing, and spending discipline.
However, while these approvals are encouraging, investors should also be aware that…
Read the full narrative on Guardant Health (it’s free!)
Guardant Health’s narrative projects $2.1 billion revenue and $105.5 million earnings by 2029.
Uncover how Guardant Health’s forecasts yield a $128.33 fair value, a 8% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming revenue could reach about US$2.3 billion by 2028 with much higher margins, so this approval may either reinforce that view or force a rethink if Shield reimbursement or adoption does not unfold as smoothly as hoped.
